42 related articles for article (PubMed ID: 2157788)
1. Infertility in Fabry's Disease: role of hypoxia and inflammation in determining testicular damage.
Sansone L; Barreca F; Belli M; Aventaggiato M; Russo A; Perrone GA; Russo MA; Tafani M; Frustaci A
Front Endocrinol (Lausanne); 2024; 15():1340188. PubMed ID: 38455658
[TBL] [Abstract][Full Text] [Related]
2. The role of tubular cells in the pathogenesis of Fabry nephropathy.
Rozenfeld P; Feriozzi S; Braun F
Front Cardiovasc Med; 2024; 11():1386042. PubMed ID: 38646152
[TBL] [Abstract][Full Text] [Related]
3. A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse.
Shin SH; Park MH; Byeon JJ; Lee BI; Park Y; Ko AR; Seong MR; Lee S; Kim MR; Seo J; Jung ME; Jin DK; Shin YG
Pharmaceutics; 2018 Jun; 10(2):. PubMed ID: 29880732
[TBL] [Abstract][Full Text] [Related]
4. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.
Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G
J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295
[TBL] [Abstract][Full Text] [Related]
5. [Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].
Porubsky S
Pathologe; 2014 Nov; 35 Suppl 2():271-6. PubMed ID: 25348118
[TBL] [Abstract][Full Text] [Related]
6. Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease.
Porubsky S; Jennemann R; Lehmann L; Gröne HJ
Cell Tissue Res; 2014 Oct; 358(1):217-27. PubMed ID: 24992926
[TBL] [Abstract][Full Text] [Related]
7. Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease.
Rothhaar TL; Grösgen S; Haupenthal VJ; Burg VK; Hundsdörfer B; Mett J; Riemenschneider M; Grimm HS; Hartmann T; Grimm MO
ScientificWorldJournal; 2012; 2012():141240. PubMed ID: 22547976
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical studies in mucopolysaccharidosis type II carriers.
Schwartz IVD; Pinto LLC; Breda G; Lima L; Ribeiro MG; Mota JG; Acosta AX; Correia P; Horovitz DDG; Porciuncula CGG; Lipinski-Figueiredo E; Fett-Conte AC; Oliveira Sobrinho RP; Norato DYJ; Paula AC; Kim CA; Duarte AR; Boy R; Leistner-Segal S; Burin MG; Giugliani R
J Inherit Metab Dis; 2009 Dec; 32(6):732-738. PubMed ID: 19821143
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
11. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.
Schiffmann R; Murray GJ; Treco D; Daniel P; Sellos-Moura M; Myers M; Quirk JM; Zirzow GC; Borowski M; Loveday K; Anderson T; Gillespie F; Oliver KL; Jeffries NO; Doo E; Liang TJ; Kreps C; Gunter K; Frei K; Crutchfield K; Selden RF; Brady RO
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):365-70. PubMed ID: 10618424
[TBL] [Abstract][Full Text] [Related]
12. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
Ohshima T; Schiffmann R; Murray GJ; Kopp J; Quirk JM; Stahl S; Chan CC; Zerfas P; Tao-Cheng JH; Ward JM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1999 May; 96(11):6423-7. PubMed ID: 10339603
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal lipid storage patterns in Fabry disease.
Elleder M; Christomanou H; Kustermann-Kuhn B; Harzer K
Acta Neuropathol; 1994; 88(6):579-82. PubMed ID: 7879606
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes.
Hozumi I; Nishizawa M; Ariga T; Miyatake T
J Lipid Res; 1990 Feb; 31(2):335-40. PubMed ID: 2157788
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry's disease.
Hozumi I; Nishizawa M; Ariga T; Inoue Y; Ohnishi Y; Yokoyama A; Shibata A; Miyatake T
J Neurol Sci; 1989 May; 90(3):273-80. PubMed ID: 2500499
[TBL] [Abstract][Full Text] [Related]
16. Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease.
Ogawa K; Sugamata K; Funamoto N; Abe T; Sato T; Nagashima K; Ohkawa S
Hum Pathol; 1990 Oct; 21(10):1067-73. PubMed ID: 2120125
[TBL] [Abstract][Full Text] [Related]
17. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.
Mills K; Morris P; Lee P; Vellodi A; Waldek S; Young E; Winchester B
J Inherit Metab Dis; 2005; 28(1):35-48. PubMed ID: 15702404
[TBL] [Abstract][Full Text] [Related]
18. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
Germain DP
J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
[TBL] [Abstract][Full Text] [Related]
19. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
